Scientists Used Fruit Flies to Quickly Develop a Personalized Cancer Treatment for a Dying Man

Scientists Used Fruit Flies to Quickly Develop a Personalized Cancer Treatment for a Dying Man

Genetically engineered fruit flies are being used in early research to screen novel combinations of cancer drugs for individual patients.

(© Muhammad Mahdi Karim/Wikipedia Commons)


Keep Reading Keep Reading
David Warmflash
David Warmflash is an astrobiologist and science writer. He received his M.D. from Tel Aviv University Sackler School of Medicine, and has done post doctoral work at Brandeis University, the University of Pennsylvania, and the NASA Johnson Space Center, where he was part of the NASA's first cohort of astrobiology training fellows. He has written numerous articles covering a range of science topics, from the search for extraterrestrial life and space exploration to the origins of life, genetics, neuroscience, biotechnology, and the history of science. David’s articles have appeared in various publications, including Wired UK, Discover, Scientific American, Genetic Literacy Project, and Cricket Media. Throughout 2018, he did a blog post series on the emergence of ancient science for Vision Learning, covering thinkers from history. Many of these ancient pioneers of science also make an appearance in David's new book, "Moon: An Illustrated History: From Ancient Myths to the Colonies of Tomorrow."
Get our top stories twice a month
Follow us on
The Friday Five: Soon Band-Aids Could Be AIs

In this week's Friday Five, research on a "smart" bandage for wounds, a breakthrough in fighting inflammation, the pros and cons of a new drug for Alzheimer's, benefits of the Mediterranean diet with a twist, and we've learned to recycle a plastic that was un-recyclable.

Adobe Stock

The Friday Five covers five stories in research that you may have missed this week. There are plenty of controversies and troubling ethical issues in science – and we get into many of them in our online magazine – but this news roundup focuses on scientific creativity and progress to give you a therapeutic dose of inspiration headed into the weekend.

Keep Reading Keep Reading
Matt Fuchs

Matt Fuchs is the editor-in-chief of Leaps.org. He is also a contributing reporter to the Washington Post and has written for the New York Times, Time Magazine, WIRED and the Washington Post Magazine, among other outlets. Follow him on Twitter @fuchswriter.

Sexually Transmitted Infections are on the rise. This drug could stop them.

Cases of gonorrhea, chlamydia and syphilis soared last year, but researchers are finding that a drug known as doxy seems to reduce the number of infections.

Adobe Stock

Sexually transmitted infections (STIs) are surging across the U.S. to 2.5 million cases in 2021 according to preliminary data from the CDC. A new prevention and treatment strategy now in clinical trials may provide a way to get a handle on them.

It's easy to overlook the soaring rates of gonorrhea, chlamydia, and syphilis because most of those infections have few or no symptoms and can be identified only through testing. But left untreated, they can lead to serious damage to nerves and tissue, resulting in infertility, blindness, and dementia. Infants developing in utero are particularly vulnerable.

Keep Reading Keep Reading
Bob Roehr
Bob Roehr is a biomedical journalist based in Washington, DC. Over the last twenty-five years he has written extensively for The BMJ, Scientific American, PNAS, Proto, and myriad other publications. He is primarily interested in HIV, infectious disease, immunology, and how growing knowledge of the microbiome is changing our understanding of health and disease. He is working on a book about the ways the body can at least partially control HIV and how that has influenced (or not) the search for a treatment and cure.